Affiliations
AffiliationItem in Clipboard
Assessment of the accuracy of the Gail model in women with atypical hyperplasiaV Shane Pankratz et al. J Clin Oncol. 2008.
. 2008 Nov 20;26(33):5374-9. doi: 10.1200/JCO.2007.14.8833. Epub 2008 Oct 14. AffiliationItem in Clipboard
AbstractPurpose: An accurate estimate of a woman's breast cancer risk is essential for optimal patient counseling and management. Women with biopsy-confirmed atypical hyperplasia of the breast (atypia) are at high risk for breast cancer. The Gail model is widely used in these women, but has not been validated in them.
Patients and methods: Women with atypia were identified from the Mayo Benign Breast Disease (BBD) cohort (1967 to 1991). Their risk factors for breast cancer were obtained, and the Gail model was used to predict 5-year-and follow-up-specific risks for each woman. The predicted and observed numbers of breast cancers were compared, and the concordance between individual risk levels and outcomes was computed.
Results: Of the 9,376 women in the BBD cohort, 331 women had atypia (3.5%). At a mean follow-up of 13.7 years, 58 of 331 (17.5%) patients had developed invasive breast cancer, 1.66 times more than the 34.9 predicted by the Gail model (95% CI, 1.29 to 2.15; P < .001). For individual women, the concordance between predicted and observed outcomes was low, with a concordance statistic of 0.50 (95% CI, 0.44 to 0.55).
Conclusion: The Gail model significantly underestimates the risk of breast cancer in women with atypia. Its ability to discriminate women with atypia into those who did and did not develop breast cancer is limited. Health care professionals should be cautious when using the Gail model to counsel individual patients with atypia.
FiguresFig 1.
Cumulative incidence of invasive breast…
Fig 1.
Cumulative incidence of invasive breast cancer among women with atypical hyperplasia (atypia) as…
Fig 1.Cumulative incidence of invasive breast cancer among women with atypical hyperplasia (atypia) as a function of age. The red line represents the cumulative incidence, corrected for the competing risk of death, in the atypia cohort. For comparison, two lines representing the Gail-predicted and the baseline population risks are included. The blue line reflects the cumulative incidence predicted by the Gail model in this cohort, and the gray line represents the cumulative incidence that serves as the baseline risk for white women in the Gail model calculations.
Fig 2.
Distributions of Gail model risk…
Fig 2.
Distributions of Gail model risk probabilities in women with atypia who developed breast…
Fig 2.Distributions of Gail model risk probabilities in women with atypia who developed breast cancer (cases) and those who did not (noncases). The plot contains estimates for individualized risk at the end of the available follow-up. Given that risk predictions depend on age at benign breast disease (BBD) and length of follow-up, the risk predictions were corrected for these factors before comparison. The graph represents the percent of women whose Gail model risk predictions fell within categories ranging from 0.0 to 0.5 in 0.05 increments. Points connected with lines to facilitate comparison between case and noncase percentages. Though the cases received more predictions in the 10% to 15% interval than the noncases, their average risk prediction was slightly, although not significantly, lower.
Similar articlesMcKian KP, Reynolds CA, Visscher DW, Nassar A, Radisky DC, Vierkant RA, Degnim AC, Boughey JC, Ghosh K, Anderson SS, Minot D, Caudill JL, Vachon CM, Frost MH, Pankratz VS, Hartmann LC. McKian KP, et al. J Clin Oncol. 2009 Dec 10;27(35):5893-8. doi: 10.1200/JCO.2008.21.5079. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805686 Free PMC article.
Pankratz VS, Degnim AC, Frank RD, Frost MH, Visscher DW, Vierkant RA, Hieken TJ, Ghosh K, Tarabishy Y, Vachon CM, Radisky DC, Hartmann LC. Pankratz VS, et al. J Clin Oncol. 2015 Mar 10;33(8):923-9. doi: 10.1200/JCO.2014.55.4865. Epub 2015 Jan 26. J Clin Oncol. 2015. PMID: 25624442 Free PMC article.
Bushnaq ZI, Ashfaq R, Leitch AM, Euhus D. Bushnaq ZI, et al. Cancer. 2007 Apr 1;109(7):1247-54. doi: 10.1002/cncr.22538. Cancer. 2007. PMID: 17326050
Mazzola E, Coopey SB, Griffin M, Polubriaginof F, Buckley JM, Parmigiani G, Garber JE, Smith BL, Gadd MA, Specht MC, Guidi A, Hughes KS. Mazzola E, et al. Breast Cancer Res Treat. 2017 Sep;165(2):285-291. doi: 10.1007/s10549-017-4320-7. Epub 2017 Jun 6. Breast Cancer Res Treat. 2017. PMID: 28589368 Free PMC article. Review.
Vogel VG. Vogel VG. Diagn Cytopathol. 2004 Mar;30(3):151-7. doi: 10.1002/dc.20004. Diagn Cytopathol. 2004. PMID: 14986294 Review.
Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B. Cadiz F, et al. J Cancer. 2013 Jul 1;4(5):433-46. doi: 10.7150/jca.6481. Print 2013. J Cancer. 2013. PMID: 23833688 Free PMC article.
Klassen CL, Viers LD, Ghosh K. Klassen CL, et al. Ann Surg Oncol. 2024 May;31(5):3154-3159. doi: 10.1245/s10434-024-14957-y. Epub 2024 Feb 1. Ann Surg Oncol. 2024. PMID: 38302622 Review.
McKian KP, Reynolds CA, Visscher DW, Nassar A, Radisky DC, Vierkant RA, Degnim AC, Boughey JC, Ghosh K, Anderson SS, Minot D, Caudill JL, Vachon CM, Frost MH, Pankratz VS, Hartmann LC. McKian KP, et al. J Clin Oncol. 2009 Dec 10;27(35):5893-8. doi: 10.1200/JCO.2008.21.5079. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805686 Free PMC article.
Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL. Menes TS, et al. JAMA Oncol. 2017 Jan 1;3(1):36-41. doi: 10.1001/jamaoncol.2016.3022. JAMA Oncol. 2017. PMID: 27607465 Free PMC article.
Frank RD, Winham SJ, Vierkant RA, Frost MH, Radisky DC, Ghosh K, Brandt KR, Sherman ME, Visscher DW, Hartmann LC, Degnim AC, Vachon CM. Frank RD, et al. Cancer. 2018 Aug;124(16):3319-3328. doi: 10.1002/cncr.31528. Epub 2018 Jun 22. Cancer. 2018. PMID: 29932456 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3